Mylan CEO Heather Bresch told analysts Thursday that there are many acquisitions the generic drugmaker could make in its drive to be the industry’s leading consolidator, but that its unsolicited offer for Perrigo Co. “is the right next transaction.”
“If [Perrigo] does not happen, we are obviously looking at a lot of assets,” Ms. Bresch said during a conference call discussing the company’s second quarter results. “We want to reach critical mass ... and there’s a lot of different assets that can get us there.”
She also described the drop in Mylan’s stock since Teva Pharmaceutical Industries withdrew its $40 billion hostile bid for Mylan last week as “a short-term temporary blip.”
“We’ve taken a little bit of a traumatic hit,” Ms. Bresch said, adding that she expects the stock to recover once investors realize the value of Mylan’s business.
Ms. Bresch reiterated the company’s commitment to acquiring Perrigo, an Irish over-the-counter drug specialist. She said the combination would create “a one-of-a-kind global health care company” with complementary businesses and a diversified portfolio of products.
Mylan shareholders are scheduled to vote Aug. 28 on whether to extend a tender offer to Perrigo shareholders. Mylan, which is based in the Netherlands but maintains its operating headquarters in Cecil, is offering Perrigo shareholders $75 in cash and 2.3 Mylan shares for each of their shares.
Read More
On Wednesday, Perrigo chairman, president and CEO Joseph Papa again rebuffed Mylan’s offer, saying it seriously undervalues his company. The 16 percent slide in Mylan shares since Teva dropped its $82 per share bid for Mylan has reduced what Perrigo shareholders would receive by agreeing to a Mylan takover.
S&P Capital IQ analyst Jeffrey Loo said Perrigo shareholders will likely demand that Mylan sweeten its bid by offering more cash given what has happened to Mylan shares.
“Mylan’s stock price is not going to support the Perrigo bid,” he said, adding that Mylan seems less confident about completing the deal.
Mylan shares closed Thursday at $55.40, up 80 cents.
Before the market opened, Mylan reported net income of $167.8 million, or 32 cents per share, on sales of $2.36 billion in the second quarter vs. earnings of $125.2 million, or 32 cents per share, and sales of $1.82 billion in the year-ago quarter.
The number of diluted shares outstanding increased 31 percent from the year-ago quarter.
Mylan said adjusted earnings per share increased 32 percent to 91 cents per share.
Analysts had expected adjusted earnings of 89 cents per share on sales of $2.39 billion.
Mylan raised its earnings guidance for the year. It now expects to report adjusted per share earnings of $4.15 to $4.35 per share, up from the forecast of $4 to $4.30 per share it gave in March.
CFO John Sheehan told analysts that the company capitalized on tax benefits it expected to achieve by relocating to the Netherlands earlier this year. The company’s effective tax rate fell to 18 percent during the quarter and it is possible it will fall again in the second half, he said.
Len Boselovic: lboselovic@post-gazette.com or 412-263-1941.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.